A Single Ascending Dose Study of BTZ043

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-07

Study Completion Date

2019-03-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate safety, tolerability, and pharmacokinetics of single doses of BTZ043 in healthy adult volunteers. The study is conducted at a study centre in Germany. Up to 50 male and female participants will be included in this study in up to 5 cohorts; each cohort will consist of 10 subjects: in each cohort 8 subjects will be assigned to BTZ-043 and 2 to placebo. The doses tested will be: 125mg, 250mg, 500mg, 1000mg and 2000mg. Safety will be assessed via regular vital sign measurement, 12-lead ECG parameters, physical examination and safety laboratory assessments.

Subjects will be hospitalized from Day -1 until discharge in the morning of Day 3. After completion of all Day 3 assessments of a cohort, blinded safety data will be reviewed and the next dose increment will be decided by the Trial Steering Committee (TSC).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683

NCT01419600

Healthy

COMPLETED PHASE1

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants

NCT05143905

Safety Tolerability Pharmacokinetics +1 more

COMPLETED PHASE1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 in Healthy Japanese Participants

NCT07222254

Healthy Participants

RECRUITING PHASE1

A Trial in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated

NCT04866160

Healthy

COMPLETED PHASE1

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1060469 in Healthy Asian Male Volunteers

NCT02183545

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis Tuberculosis, Pulmonary Bacterial Infections Lung Diseases Mycobacterium Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Subjects, investigators and investigators' staff, persons performing the assessments or being responsible for determining dosing regimen/adjustments, and staff of the sponsor or data analysts, will remain blinded from the time of randomization until database lock, using the following methods: randomization data, including any documentation identifying the treatment allocation, are kept strictly confidential until the time of unblinding with the following exceptions: staff responsible for study drug management (i.e. the staff in the CRO CTS department preparing the IMP).

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1: 125 mg BTZ-043 fasting

N=8, 125 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose

Group Type EXPERIMENTAL

BTZ-043

Intervention Type DRUG

Powder and solvent for oral suspension

Cohort 1: Placebo

N=2, matching placebo, powder and solvent for oral solution, single dose

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching placebo: powder and solvent for oral suspension

Cohort 2: 250 mg BTZ-043 fasting

N=8, 250 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose

Group Type EXPERIMENTAL

BTZ-043

Intervention Type DRUG

Powder and solvent for oral suspension

Cohort 2: Placebo

N=2, matching placebo, powder and solvent for oral solution, single dose

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching placebo: powder and solvent for oral suspension

Cohort 3: 500 mg BTZ-043 fasting

N=8, 500 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose

Group Type EXPERIMENTAL

BTZ-043

Intervention Type DRUG

Powder and solvent for oral suspension

Cohort 3: Placebo

N=2, matching placebo, powder and solvent for oral solution, single dose

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching placebo: powder and solvent for oral suspension

Cohort 4: 1000 mg BTZ-043 fasting

N=8, 1000 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose

Group Type EXPERIMENTAL

BTZ-043

Intervention Type DRUG

Powder and solvent for oral suspension

Cohort 4: Placebo

N=2, matching placebo, powder and solvent for oral solution, single dose

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching placebo: powder and solvent for oral suspension

Cohort 5: 2000mg BTZ-043 fasting

N=8, 2000 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose

Group Type EXPERIMENTAL

BTZ-043

Intervention Type DRUG

Powder and solvent for oral suspension

Cohort 5: Placebo

N=2, matching placebo, powder and solvent for oral solution, single dose

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching placebo: powder and solvent for oral suspension

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BTZ-043

Powder and solvent for oral suspension

Intervention Type DRUG

Placebo

Matching placebo: powder and solvent for oral suspension

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provide written informed consent
* Healthy male or female subjects aged between ≥18 and ≤55 years at screening who are able to read, write, and fully understand the German language
* BMI between ≥18 and ≤30 kg/m2, with a body weight between ≥55 and ≤90 kg at screening
* Vital signs within range: pulse rate 50-90 bpm, systolic blood pressure 90-140 mmHg, diastolic blood pressure 50-90 mmHg
* No clinically significant findings in laboratory tests
* Women must be of non-childbearing potential, that is, either postmenopausal or premenopausal with documented tubal ligation or hysterectomy or women who are at least 6 weeks post-surgical bilateral oophorectomy
* Male subjects must agree to use a condom with spermicide when engaging in sexual intercourse during the study period and for 2 months after study drug dosing, if they have not had a vasectomy at least 6 months before study start
* Male subjects must not donate sperm during the study and for 2 months after study drug dosing
* Able to swallow the amount of drug in succession
* Agree not to donate blood (or bloodcomponents) until 1 month after receiving study drug
* Normal consumption of alcohol
* Willing to forgo sunbathing and prolonged exposure to sunlight during the study period
* Willing to forgo strenuous exercise from 72 hours prior to admission until discharge

Exclusion Criteria

* Any known chronic systemic viral infection
* Any relevant systemic infection or other systemic illness
* Vaccination 30 days prior to drug administration
* Known hypersensitivity to any of the excipients of the study drug
* A clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders, or have a clinically relevant surgical history or any other medical condition
* History of or current alcohol or illicit drug abuse
* Positive results in the urine drug screen or blood alcohol test at admission
* Current or recent (within the past 3 months before drug administration) use of tobacco or other nicotine-containing product or positive results of cotinine test at screening or admission
* Use of any prescription or over-the-counter (OTC) drug or herbal product within 14 days before drug administration with exception for sporadic use of ibuprofen or paracetamol for example in case of pain
* Use of any known drug metabolism enzyme-altering drug or supplement within 14 days before dosing or consumption of foods or beverages containing grapefruit within 48 hours before admission
* ECG findings in the screening ECG of QTcF-interval over 450 ms; atrioventricular (AV) block with PR-interval over 200 ms, prolongation of the QRS complex over 120 ms, or other changes in the ECG that are clinically relevant as per discretion of the investigator
* Long QT syndrome, or family history of long QT syndrome or sudden death of unknown or cardiac-related cause
* Use or planned necessary use of any QT-prolonging agents
* Participation in another investigational drug study within the previous 30 days before drug administration
* Any donation of blood, plasma, or platelets or significant loss of blood within the previous 30 days before drug administration
* Previous randomization in this study
* Volunteer unwilling or unable to comply with protocol requirements in the judgment of the investigator
* Vulnerable subject (e.g. person is kept in detention)
* Employees of the sponsor or subjects who are employees or relatives of the investigator

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes